Insurance and Provider Markets
Featured Topics
Lead story
Other featured articles
-
Biosimilar Drugs Underutilized Due to Commercial Insurance Restrictions
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
Posted in -
Tweak the Affordable Care Act to Mandate Backstop Health Insurance
Universal coverage could be achieved through a “backstop” insurance that auto-enrolls uninsured patients when they seek care.
Posted in -
Largest Medicare Advantage Plans Pay Big Markups for Dialysis
Large dialysis chains charge Medicare Advantage plans 27% more than the traditional, fee-for-service Medicare program.
Posted in -
The Supreme Court Left Millions of Americans Uninsured: Here’s What Congress Can Do to Cover Them
Congress can expand healthcare to millions of Americans by enrolling individuals in the 12 states that did not expand Medicaid.
Posted in
About this section
Competition is essential for a properly functioning marketplace, but industry consolidation, insurance complexity and other factors are barricading healthcare consumers from the benefits of good commerce. Schaeffer Center analysts explore ways to remove those obstacles to efficiency, while also promoting optimal care.
Our Experts On Insurance and Provider Markets
Our Work In Insurance and Provider Markets
-
Eliminating Small Marketplace Premiums Could Meaningfully Increase Insurance Coverage
Matthew Fiedler estimate that 404,000 Marketplace enrollees in the states served by HealthCare.gov currently owe a small positive premium (defined as a positive premium of less than 0.5% of the gross premium of the enrollee’s plan, which translates to around $3 per month on average).
-
Value Defects In The Health Services Sector
As of 2021, US health care expenditures exceed $3.8 trillion. It’s no secret that health care is nearly as wasteful in spending on value defects—behaviors that needlessly reduce quality, negatively impact the patient experience, or add to total costs of care—as it is in delivering clinical benefits.
Categorized in -
New Evidence Suggests a Lack of Cost-Shifting in Prescription Drug Markets
Recent legislative efforts to regulate drug prices have reignited debates about the interaction between price setting in public insurance programs and commercial market spending.
Categorized in -
Revisiting Early Structural Findings of Asymmetric Information’s Non-Existence in Health Insurance
AHRQ Postdoctoral Research Fellow revisits an early structural model that tests for asymmetric information in health insurance.
Categorized in -
The Case for Replacing “Silver Loading”
An analysis of how a public option may or may not reduce healthcare costs in the U.S.
-
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
Research from Schaeffer Center experts Darius Lakdawalla and Meng Li in JAMA Network Open finds U.S. insurers could use drug manufacturer rebates to lower retail pharmacy prices and reduce patient out-of-pocket burden by 38% on average, or 70% in the most competitive drug classes.
Categorized in